Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17

AIDS Research and Human Retroviruses

Volumn 14, Issue 9, 1998, Pages 741-749

  Zimmerman, D H ^a   Ulrich, J Terry ^b   Wright, Craig ^c   Lloyd, J P ^a   Winship, M D ^a   Sarin, P S ^a  

^a Cel Sci Corporation   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NOVAVAX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; AMINO ACID; CROSS REACTING ANTIBODY; CROSS REACTING ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; KEYHOLE LIMPET HEMOCYANIN; LIPOSOME; PHOSPHORYL LIPID A; SYNTHETIC PEPTIDE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; CROSS REACTION; DRUG FORMULATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MOUSE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SCID MOUSE;

EID: 0032503578     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.741     Document Type: Article

References (27)

1. Esparza J, Osmanov S, and Heyward WL: HIV preventive vaccines. Progress to date. Drugs 1995;50:792-804.
2. Haynes BF: Scientific and social issues of human immunodeficiency virus vaccine development. Science 1993;260: 1279-1286.
3. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Wagner KF, McNeil JG, McCutchen E, and Burke DS: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996; 173:340-348.
4. Haynes BF, Pantaleo G, and Fauci AS: Toward an understanding of protective immunity to HIV infection. Science 1996; 271:324-328.
5. Walker BD and Plata F: Cytotoxic T lymphocytes against HIV. AIDS 1990;4:177-184.
6. Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, Corey LC, Bolognesi DP, and Weinhold KJ: Clade B based HIV-1 vaccines elicit cross clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-1401.
7. Klein MR, Van Baalen CA, Holwerda AM, Kerkhof-Garde SR, Bende RJ, Keet IPM, Eeftinck-Schattenkerk JKM, Osterhaus ADME, Scuitemaker H, and Midema F: Kinetics of Gag specific T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long term asymptomatics. J Exp Med 1995;181:1365-1372.
8. Sarin PS, Mora CA, Naylor PH, Markham R, Schwartz D, Kahn J, Heseltine P, Gazzard B, Youle M, Rios A, and Goldstein AL: HIV-1 p17 synthetic peptide vaccine HGP-30. Induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice. Cell Mol Biol 1995;41:401-407.
9. Gazzard B, Youle M, MacDonald V, O'Toole CM, Stambuk D, Rios A, Achour A, Zagury D, Naylor PH, Sarin PS, and Goldstein AL: Safety and immunogenicity of HGP-30. Evaluation of a synthetic HIV-1 p17 vaccine in healthy HIV seronegative volunteers. Vaccine Res 1992;1:129-135.
10. Naylor PH, Sztein MB, Wada S, Maurer S, Hilterman D, Kirkley JE, Naylor CW, Zook BC, Hitzelberg RA, Gibbs CJ, Zagury D, Achour A, Youle M, Rios A, Sarin PS, and Goldstein AL: Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17 based synthetic peptide AIDS vaccine HGP-30/KLH. Int J Immunopharmacol 1991;13(Suppl. 1):117-127.
11. Achour A, Picard D, Zagury D, Sarin PS, Gallo RC, Naylor PH, and Goldstein AL: HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17 is a target for cytotoxic lymphocytes in HIV infected individuals. Proc Natl Acad Sci USA 1990;87:7045-7049.
12. Okuda K, Kaneko T, Yamakawa T, Tanaka S, Shigematsu T, Yamamoto A, Hamajima K, Nakajima K, Kawamoto S, and Phanuphak P: Strong immunogenicity of multicomponent peptide vaccine developed with branched lysine oligopeptide method for human immunodeficiency virus. J Mol Recognit 1993;6:101-109.
13. Okuda K, Kaneko T, Yamakawa T, Tanaka S, Aoki I, Hamajima K, and Kawamoto S: Strong synergistic effects of multicomponent vaccine for human immunodeficiency virus infection. J Clin Lab Immunol 1993;40:97-113.
14. Bukawa H, Sekigawa KI, Hamajima K, Fukushima J, Yamada Y, Kiyono H, and Okuda K: Neutralization of HIV-1 by secretory IgA induced oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nature Med 1995;1:681-685.
15. Harrer E, Harrer T, Buckbinder S, Yilma T, Johnson RP, and Walker BD: HIV specific CTL response in healthy long term seropositive persons. In: IXth Int. Conf. on AIDS, Berlin, 1993. p. 215. [Abstract POA22-0484]
16. Sarin PS, Markham R, Schwartz D, Naylor PH, Kahn J, Heseltine P, Gazzard B, Youle M, Rios A, and Goldstein AL: Cytotoxic and humoral immune responses to HIV-1 p17 synthetic peptide HGP-30 in human volunteers. Vaccine Res 1994;3:49-57.
17. Kahn J, Talmadge JE, Heseltine P, Murear N, Gendelman HE, Coleman R, Kelsey L, Beckner S, Winship P, and Kahn J: Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice. Vaccine (in press).
18. Palker TJ, Clark ME, Langlois AJ, Matthews TJ, Weinhold KJ, Randall RR, Bologuesi DP, and Haynes BF: Type specific neutralization of the human immunodeficiency virus with antibodies to env encoded synthetic peptides. Proc Natl Acad Sci USA 1988;85:1932-1936.
19. Clerici M and Shearer GM: A Th-1 → Th-2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
20. 3 branched peptide vaccine. J Infect Dis 1996; 173:330-339.
21. Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold KJ, Matthews TJ, Esterlitz JR, Sinangil F, and Fast PE: Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. Ann Intern Med 1996;125:270-279.
22. Fleury P, Janvier G, Pialoux G, Buseyne F, Robertson MN, Tartaghia J, Paoletti E, Kieny MP, Excler JL, and Riviere Y: Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1) negative volunteers immunized with a recombinant gp160. J Infect Dis 1996;174:734-738.
23. Van Cott TC, Bethke FR, Burke DS, Redfield RR, and Birx DL: Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol 1995;155:4100-4110.
24. Bolognesi DP: Overview of HIV vaccine development. Antibiot Chemother 1996;48:63-77.
25. Connor RJ, Korber BTM, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, and Kunstman KJ: Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol 1998;78:1552-1576.
26. Pincus SH, Messer KG, Cole R, Ireland R, Van Cott TC, Pinter A, Schwartz DH, Graham BS, and Gorse GJ: Vaccine specific antibody responses induced by HIV-1 envelope subunit vaccines. J Immunol 1997;158:3511-3520.
27. McDougal JS, Kennedy MS, Nicholson JKA, Spira JJ, Jaffe HW, Kaplan JE, Fishbein DB, O'Malley P, Aloisio CH, Black CM, Hubbard M, and Reimer CB: Antibody response to human immunodeficiency virus in homosexual men. J Clin Invest 1987; 80:316-324.